XML 22 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2014
Mar. 31, 2014
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Maximum success-based milestone payments $ 55,000,000            
Amount of certain milestones achieved in account receivable     $ 12,903,000   $ 12,903,000   $ 12,436,000
Revenue recognized under collaboration agreement     1,783,000 $ 1,079,000 3,112,000 $ 1,697,000  
Estimated deferred revenue recognized within one year     5,635,000   5,635,000   4,627,000
Celgene Corporation [Member] | Collaborative Arrangement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Amount of certain milestones achieved in account receivable             $ 6,000,000
Revenue recognized under collaboration agreement     200,000 1,100,000 1,200,000 1,700,000  
Deferred revenue recorded under collaboration agreement     7,600,000   7,600,000    
Estimated deferred revenue recognized within one year     2,100,000   2,100,000    
Celgene Corporation [Member] | Upfront Payment Arrangement [Member] | Collaborative Arrangement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Collaboration agreement upfront payment   $ 5,800,000          
Celgene Corporation [Member] | Maximum [Member] | Collaborative Arrangement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Maximum success-based milestone payments         17,000,000    
Merck Sharp & Dohme Corp. [Member] | Clinical Research Collaborative Arrangement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue recognized under collaboration agreement     1,600,000 $ 0 1,800,000 $ 0  
Deferred revenue recorded under collaboration agreement     $ 1,300,000   $ 1,300,000    
Collaborative agreement period         1 year    
Merck Sharp & Dohme Corp. [Member] | Maximum [Member] | Clinical Research Collaborative Arrangement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Maximum success-based milestone payments         $ 4,000,000